A Multicentre, Randomized, Double-blind, Placebo-controlled, phase III study to evaluate the efficacy and safety of Pioglitazone co-administration in patients with type II diabetes with insufficient glycemic control with Metformin and Empagliflozin combination therapy

Type 2 diabetes mellitus (T2DM)

Change from Baseline in HbA1c at Week 24 of the Treatment

Change from Baseline in HbA1c at Week 12 of the Treatment, Change from Baseline in fasting plasma glucose (FPG) at Week 12 and 24 of the Treatment, Proportion (%) of subjects who achieved HbA1c < 6.5% at Week 24 of the Treatment, Proportion (%) of subjects who achieved HbA1c < 7.0% at Week 24 of the Treatment, Change from Baseline in lipid profile (total cholesterol, LDL-C, HDL-C, and TG) levels at Week 12 and 24 of the Treatment, Change from Baseline in insulin resistance (HOMA-IR) and insulin secretion ability (HOMA-β) at Week 12 and 24 of the Treatment, Change from Baseline in liver function indicators (AST, ALT) at Week 12 and 24 of the Treatment, Proportion (%) of subjects who received a rescue medication at Week 12 and 24 of the Treatment, Change from Baseline in body weight at Week 12 and 24 of the Treatment, Change from Baseline in blood pressure (SBP, DBP) at Week 12 and 24 of the Treatment, Change from Baseline in heart rate at Week 12 and 24 of the Treatment, Change from Baseline in waist circumference at Week 12 and 24 of the Treatment

No related papers found yet.

Poland